227 related articles for article (PubMed ID: 22509934)
41. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
42. RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer.
Yu F; Wang Y; Xiao Y; He Y; Luo C; Duan D; Li C; Xu S; Xiang T
Mol Immunol; 2014 May; 59(1):100-9. PubMed ID: 24534066
[TBL] [Abstract][Full Text] [Related]
43. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
44. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
45. [Inhibitory effect of siRNA targeting ADAM17 on the proliferation of prostate cancer PC-3 cells].
Lin F; Lin P; Liu X; Li D; Liu ZJ; Zou HF; Jiang Y; Zhao XF; Feng JL; Yu XG
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):687-91. PubMed ID: 22934512
[TBL] [Abstract][Full Text] [Related]
46. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
47. ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.
Trad A; Hansen HP; Shomali M; Peipp M; Klausz K; Hedemann N; Yamamoto K; Mauermann A; Desel C; Lorenzen I; Lemke H; Rose-John S; Grötzinger J
Cancer Immunol Immunother; 2013 Mar; 62(3):411-21. PubMed ID: 22940887
[TBL] [Abstract][Full Text] [Related]
48. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.
Stamova S; Feldmann A; Cartellieri M; Arndt C; Koristka S; Apel F; Wehner R; Schmitz M; Bornhäuser M; von Bonin M; Ehninger G; Bartsch H; Bachmann M
Anal Biochem; 2012 Apr; 423(2):261-8. PubMed ID: 22274538
[TBL] [Abstract][Full Text] [Related]
49. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
[TBL] [Abstract][Full Text] [Related]
50. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
51. A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells.
Brey CU; Proff J; Teufert N; Salzer B; Brozy J; Münz M; Pendzialek J; Ensser A; Holter W; Lehner M
Sci Rep; 2018 Nov; 8(1):17453. PubMed ID: 30487534
[TBL] [Abstract][Full Text] [Related]
52. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA
Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411
[TBL] [Abstract][Full Text] [Related]
53. Specific targeting of cytokine-secreting cells: a bispecific diabody recognizing human interleukin-6 and CD3 induces T cell-mediated killing.
Krebs B; Ackermann B; Rose-John S
J Interferon Cytokine Res; 1998 Sep; 18(9):783-91. PubMed ID: 9781818
[TBL] [Abstract][Full Text] [Related]
54. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
[TBL] [Abstract][Full Text] [Related]
55. Development of sandwich ELISA for detection and quantification of human and murine a disintegrin and metalloproteinase17.
Trad A; Hedemann N; Shomali M; Pawlak V; Grötzinger J; Lorenzen I
J Immunol Methods; 2011 Aug; 371(1-2):91-6. PubMed ID: 21726562
[TBL] [Abstract][Full Text] [Related]
56. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
57. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
Xiao LJ; Lin P; Lin F; Liu X; Qin W; Zou HF; Guo L; Liu W; Wang SJ; Yu XG
Int J Oncol; 2012 May; 40(5):1714-24. PubMed ID: 22200661
[TBL] [Abstract][Full Text] [Related]
58. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
59. [Biologic properties of an anti-human ovarian carcinoma/anti-human CD3 single chain bispecific antibody].
Yang JZ; Zhang Z; Ma L; Yao XS; Zhou MQ; Wang XB; Wang XN
Ai Zheng; 2005 Jul; 24(7):787-91. PubMed ID: 16004801
[TBL] [Abstract][Full Text] [Related]
60. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
